Kara Duffy
YOU?
Author Swipe
View article: Supplemental Figure 1 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study
Supplemental Figure 1 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study Open
Supplemental Figure 1 shows the analytic sample flow chart.
View article: Supplemental Table 4 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study
Supplemental Table 4 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study Open
Supplemental Table 4 provides prevalence rates of any tobacco use using TNE-2 cut-points.
View article: Supplemental Figure 1 from Urinary Cotinine and Cotinine + Trans-3′-Hydroxycotinine (TNE-2) Cut-points for Distinguishing Tobacco Use from Nonuse in the United States: PATH Study (2013–2014)
Supplemental Figure 1 from Urinary Cotinine and Cotinine + Trans-3′-Hydroxycotinine (TNE-2) Cut-points for Distinguishing Tobacco Use from Nonuse in the United States: PATH Study (2013–2014) Open
This flow diagram outlines exclusion criteria that led to our final analytic sample. All N s are unweighted. Abbreviations: P30D= past 30-days. *This is the reference category for the exclusive or polytobacco cigarette use groups. Addition…
View article: Supplemental Table 1 from Urinary Cotinine and Cotinine + Trans-3′-Hydroxycotinine (TNE-2) Cut-points for Distinguishing Tobacco Use from Nonuse in the United States: PATH Study (2013–2014)
Supplemental Table 1 from Urinary Cotinine and Cotinine + Trans-3′-Hydroxycotinine (TNE-2) Cut-points for Distinguishing Tobacco Use from Nonuse in the United States: PATH Study (2013–2014) Open
This table provides Receiver Operating Curve (ROC) characteristics and optimal cut-point to distinguish past 30-day daily and non-daily cigarette users from non-users*, overall and by sex and race/ethnicity.
View article: Supplemental Table 5 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study
Supplemental Table 5 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study Open
Supplemental Table 5 provides Wave 1 and Wave 4 cotinine cut-points for any tobacco use.
View article: Supplemental Table 6 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study
Supplemental Table 6 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study Open
Supplemental Table 6 provides Wave 1 and Wave 4 TNE-2 cut-points for any tobacco use.
View article: Supplemental Table 3 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study
Supplemental Table 3 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study Open
Supplemental Table 3 provides prevalence rates of any tobacco use using cotinine cut-points.
View article: Data from Urinary Cotinine and Cotinine + Trans-3′-Hydroxycotinine (TNE-2) Cut-points for Distinguishing Tobacco Use from Nonuse in the United States: PATH Study (2013–2014)
Data from Urinary Cotinine and Cotinine + Trans-3′-Hydroxycotinine (TNE-2) Cut-points for Distinguishing Tobacco Use from Nonuse in the United States: PATH Study (2013–2014) Open
Background:Determine the overall, sex-, and racially/ethnically-appropriate population-level cotinine and total nicotine equivalents (TNE-2, the molar sum of the two major nicotine metabolites) cut-points to distinguish tobacco users from …
View article: Supplemental Table 2 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study
Supplemental Table 2 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study Open
Supplemental Table 2 provides demographic and tobacco use characteristics of any tobacco users.
View article: Supplemental Table 1 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study
Supplemental Table 1 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study Open
Supplemental Table 1 provides demographic and tobacco use characteristics of exclusive and polytobacco users.
View article: Supplemental Table 4 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.
Supplemental Table 4 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study. Open
Supplemental Table 4 provides prevalence rates of any tobacco use using TNE-2 cut-points.
View article: Supplemental Table 1 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.
Supplemental Table 1 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study. Open
Supplemental Table 1 provides demographic and tobacco use characteristics of exclusive and polytobacco users.
View article: Supplemental Table 5 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.
Supplemental Table 5 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study. Open
Supplemental Table 5 provides Wave 1 and Wave 4 cotinine cut-points for any tobacco use.
View article: Supplemental Table 5 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.
Supplemental Table 5 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study. Open
Supplemental Table 5 provides Wave 1 and Wave 4 cotinine cut-points for any tobacco use.
View article: Supplemental Table 1 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.
Supplemental Table 1 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study. Open
Supplemental Table 1 provides demographic and tobacco use characteristics of exclusive and polytobacco users.
View article: Supplemental Figure 1 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.
Supplemental Figure 1 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study. Open
Supplemental Figure 1 shows the analytic sample flow chart.
View article: Data from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.
Data from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study. Open
Background: Sex and racial/ethnic identity specific cut-points for validating tobacco use using Wave 1 (W1) of the PATH Study were published in 2020. The current study establishes predictive validity of the W1 (2014) urinary cotinine and T…
View article: Supplemental Table 2 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.
Supplemental Table 2 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study. Open
Supplemental Table 2 provides demographic and tobacco use characteristics of any tobacco users.
View article: Supplemental Figure 1 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.
Supplemental Figure 1 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study. Open
Supplemental Figure 1 shows the analytic sample flow chart.
View article: Supplemental Table 2 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.
Supplemental Table 2 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study. Open
Supplemental Table 2 provides demographic and tobacco use characteristics of any tobacco users.
View article: Supplemental Table 3 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.
Supplemental Table 3 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study. Open
Supplemental Table 3 provides prevalence rates of any tobacco use using cotinine cut-points.
View article: Supplemental Table 4 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.
Supplemental Table 4 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study. Open
Supplemental Table 4 provides prevalence rates of any tobacco use using TNE-2 cut-points.
View article: Supplemental Table 6 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.
Supplemental Table 6 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study. Open
Supplemental Table 6 provides Wave 1 and Wave 4 TNE-2 cut-points for any tobacco use.
View article: Supplemental Table 3 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.
Supplemental Table 3 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study. Open
Supplemental Table 3 provides prevalence rates of any tobacco use using cotinine cut-points.
View article: Supplemental Table 6 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study.
Supplemental Table 6 from Validating Wave 1 (2014) urinary cotinine and TNE-2 cut-points for differentiating Wave 4 (2017) cigarette use from non-use in the US using data from the PATH Study. Open
Supplemental Table 6 provides Wave 1 and Wave 4 TNE-2 cut-points for any tobacco use.
View article: Supplemental Table 3 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study
Supplemental Table 3 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study Open
Supplemental Table 3 provides prevalence rates of any tobacco use using cotinine cut-points.
View article: Supplemental Table 6 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study
Supplemental Table 6 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study Open
Supplemental Table 6 provides Wave 1 and Wave 4 TNE-2 cut-points for any tobacco use.
View article: Supplemental Table 3 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study
Supplemental Table 3 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study Open
Supplemental Table 3 provides prevalence rates of any tobacco use using cotinine cut-points.
View article: Supplemental Figure 1 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study
Supplemental Figure 1 from Validating Wave 1 (2014) Urinary Cotinine and TNE-2 Cut-points for Differentiating Wave 4 (2017) Cigarette Use from Non-use in the United States Using Data from the PATH Study Open
Supplemental Figure 1 shows the analytic sample flow chart.